New class of menopause drugs reduces number and severity of hot flushes

March 14, 2018

A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days.

The treatment, tested by scientists at Imperial College London, also reduces the severity of hot flushes by over a third within three days of taking it.

The research, funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), is a new in-depth analysis of data collected from a clinical trial initially published last year.

The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.

The original drug trial, which was a randomised, double-blind, placebo-controlled trial, involved 37 menopausal women aged between 40 and 62 years old - and who experienced seven or more hot flushes a day.

Participants were randomly chosen to first receive either an 80mg daily dose of the drug, called MLE4901, or a placebo over the course of a four-week period. They then switched to receive the other tablet for an additional four weeks. This ensured the women acted as their own controls during the study, and the effects of the drug were clear.

The researchers found that the compound MLE4901 significantly reduced the average total number of flushes during the four-week treatment period, as well as their severity, compared to when the patients received the placebo for four weeks.

The new analysis shows the compound has a significant effect within just three days explains Professor Waljit Dhillo, an NIHR Research Professor from the Department of Medicine at Imperial: "We already knew this compound could be a game-changer for menopausal women, and get rid of three-quarters of their hot flushes in four weeks. But this new analysis confirms the beneficial effect is obtained very quickly - within just three days."

Professor Dhillo explains this specific compound will not be taken further in trials, due to side effects that may affect liver function. However, two very similar drugs, which also block NKB but do not appear to carry these side effects have entered larger patient trials, with one such trial launched in the US last year.

The menopause occurs when oestrogen levels fall, typically around 45 to 55 years of age, which leads to periods stopping, the inability to have children naturally, and a number of physical changes, including menopausal flushing and/or sweating.

For many women, these hot flushes may be little more than an uncomfortable inconvenience. But for some, frequent severe episodes can lead to clothes and bed sheets drenched in sweat, as well as relentless waking from sleep which impacts their working, social and home lives.

The new experimental compounds are thought to work by blocking the action of a brain chemical called neurokinin B (NKB). Previous animal and human trials have shown increased levels of NKB may trigger hot flushes. The drug compound is thought to prevent NKB activating temperature control areas within the brain - which appears to halt hot flushes.

The new data also revealed that the drug was as effective at improving daytime flush symptoms as it was at improving night time symptoms. Furthermore, the women reported a 82 percent decrease in the amount their hot flushes interrupted their sleep, and a 77 percent reduction in interruption to their concentration.

However, the team says further research is needed to reveal whether improvements in sleep and concentration were simply due to less disruption from hot flushes, or if the compound also affected sleep and concentration pathways in the brain.

Dr Julia Prague, first author of the study, explained: "As NKB has many targets of action within the brain the potential for this drug class to really improve many of the symptoms of the menopause, such as hot flushes, difficulty sleeping, weight gain, and poor concentration, is huge. To see the lives of our participants change so dramatically and so quickly was so exciting, and suggests great promise for the future of this new type of treatment."

The hope is these types of compounds may provide women with an alternative to Hormone Replacement Therapy, the current treatment for symptoms of the menopause. This therapy, which contains oestrogen, may increase the relative risk of breast cancer and can increase the risk of blood clots. This means that many women cannot take HRT to relieve their menopausal symptoms.

Professor Dhillo added: "This class of new drugs may provide women with a much-needed alternative to HRT. "

He added that the discovery of this class of compound, which was previously developed as a drug for schizophrenia, highlights the importance of collaboration and investment in British research.

Professor Dhillo said: "Thanks to Government funding from the MRC and NIHR, and collaboration with pharmaceutical companies, we were able to identify this new therapeutic use for the compound - which had previously been sitting on the shelf unused - and within three years show this type of drug may make a tangible difference to the lives of millions of women."
-end-
The research was funded by the Medical Research Council and the National Institute for Health Research. The study was supported by the NIHR/Wellcome Trust Clinical Research Facility.

Imperial College London

Related Menopause Articles from Brightsurf:

Cannabis use for menopause symptom management
CLEVELAND, Ohio (September 28, 2020)--As legislation relaxes regarding cannabis, it is being used to manage numerous chronic health conditions and mood symptoms.

Could your menopause symptoms be hard on your heart?
Menopause is accompanied by numerous symptoms that can interfere with a woman's quality of life, but can they also cause health problems?

Research provides new insights into menopause and weight gain
Can women in menopause get the benefits of hormone replacement therapy without the health risks?

Executive function in women post-menopause
Assessing adverse childhood experiences and current anxiety and depression symptoms may help ease cognitive distress in women who have undergone a surgical menopause for cancer risk-reduction, or RRSO, according to a new study published in Menopause.

An apple a day might help keep bothersome menopause symptoms away
A healthy diet rich in fruits and vegetables is known to benefit the human body in so many ways.

Menopause timing hard to determine in every third woman
Is it possible to investigate menopausal age, or not? In more than one in three women aged 50, the body provides no clear answer about the menopause, Swedish study shows.

Having less sex linked to earlier menopause
Women who engage in sexual activity weekly or monthly have a lower risk of entering menopause early relative to those who report having some form of sex less than monthly, according to a new UCL study.

Getting a good night's sleep complicated by menopause
The value of a good night's sleep can't be underestimated.

Early menopause predictor of heart disease
Women who reach menopause before the age of 50 have an increased risk of cardiovascular disease, according to researchers from The University of Queensland.

Microbes are a key marker of vaginal health during menopause
Certain species of bacteria are actually necessary to maintain vaginal health.

Read More: Menopause News and Menopause Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.